<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888978</url>
  </required_header>
  <id_info>
    <org_study_id>2011-384</org_study_id>
    <nct_id>NCT01888978</nct_id>
  </id_info>
  <brief_title>Molecularly Tailored Therapy for Pancreas Cancer</brief_title>
  <official_title>A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient therapy is tailored according to the molecular profile of the patient's tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is for patients with metastatic pancreatic cancer (cancer that has spread to other
      parts of the body). The purpose of this study is to determine whether molecularly tailored
      therapy can improve the effectiveness of standard chemotherapy combinations for patients with
      metastatic pancreatic cancer. A series of special tests will be performed on a sample of
      tumor, and based on the results subjects will be assigned to one of seven chemotherapy
      treatments, with each being the combination of two standard chemotherapies. Each of these
      combinations has been safely used in patients with pancreatic or other types of cancer. The
      purpose of this study is to to determine the ability to personalize therapy in this manner,
      and to determine how many patients a larger study would need. A second purpose is not to
      determine if one doublet is better than another. Rather, this second purpose is to show that
      for all patients enrolled in this protocol who have been assigned a doublet based on their
      tumor's molecular analysis (molecular tailoring), treatment response will be better than
      would be expected compared to patients who have been treated in the past with no molecular
      tailoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 24, 2018</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timing of biopsy and treatment</measure>
    <time_frame>1 year</time_frame>
    <description>The number of days from study entry to biopsy to molecular results to first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimates for future trials</measure>
    <time_frame>1 year</time_frame>
    <description>objective response rate, proportions of patients with each molecular profile, timing of biopsy and therapy results, usefulness of molecular profile results and adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>1 year</time_frame>
    <description>confirmed classification of stable disease, partial response, or complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time in days from study entry until progression or death</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Modified FOLFOX-6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ox-Tax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tax-Iri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-Ox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-5FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-Tax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-OX</intervention_name>
    <arm_group_label>Gem-Ox</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-5FU</intervention_name>
    <arm_group_label>Gem-5FU</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-Tax</intervention_name>
    <arm_group_label>Gem-Tax</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>Docetael</other_name>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified FOLFOX-6</intervention_name>
    <arm_group_label>Modified FOLFOX-6</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-Fluorourcil</other_name>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ox-Tax</intervention_name>
    <arm_group_label>Ox-Tax</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Oxalipaltin</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>Irinotecan</other_name>
    <other_name>CPT-11</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tax-Iri</intervention_name>
    <arm_group_label>Tax-Iri</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven pancreatic adenocarcinoma with measurable disease

          -  Biopsy accessible tumor deposits

          -  ECOG performance status 0-2

          -  Age &gt;/= 18 years

          -  Subjects with no brain metastases or history of previously treated brain metastases

          -  Adequate hepatic, renal, and bone marrow function

          -  Partial thromboplastin time must be &lt;/= 1.5 x upper normal limit of institution's
             normal range and INR &lt; 1.5

          -  Life expectancy &gt; 12 weeks

          -  Women of childbearing potential must have a negative seum pregnancy test within 14
             days prior to initiation of treatment

          -  Subject is capable of understanding and complying with parameters as outlines in the
             protocol and able to sign and date the consents

        Exclusion Criteria:

          -  CNS metastases which do not meet criteria outlines in inclusion criteria

          -  Active severe infection or known chronic infection with HIV or hepatitis B virus

          -  Cardiovascular disease

          -  Life threatening visceral disease or other severe concurrent disease

          -  Women who are pregnant, breastfeeding, or women of childbearing potential not using
             dual forms of effective contraception

          -  Anticipated patient survival under 3 months

          -  Patients receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to gemcitabine, oxaliplatin, 5-FU, docetaxel or irinotecan

          -  Uncontrolled intercurrent illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pishvaian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University- Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Montgomery Medical Center</name>
      <address>
        <city>Olney</city>
        <state>Maryland</state>
        <zip>20832</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

